We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.38B
1-Year Est. Return 63.08%
This Fund
S&P 500
This Quarter Est. Return
+9.09%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.62%
AUM
$5.62B
AUM Growth
+$874M
Cap. Flow
+$536M
Cap. Flow %
9.53%
Top 10 Hldgs %
66.07%
Holding
710
New
128
Increased
146
Reduced
103
Closed
149

Top Buys

Rank Stock Value
1
ATVI
Activision Blizzard
ATVI
+$779M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$358M
3
NEWR
New Relic, Inc.
NEWR
+$258M
4
DEN
Denbury Inc.
DEN
+$175M
5
VMW
VMware, Inc
VMW
+$165M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$230M
2
PDCE
PDC Energy, Inc.
PDCE
+$221M
3
UNVR
Univar Solutions Inc.
UNVR
+$219M
4
FOCS
Focus Financial Partners Inc. Class A
FOCS
+$146M
5
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$141M

Sector Composition

Rank Sector Weight
1 Technology 34.82%
2 Healthcare 28.77%
3 Real Estate 5.15%
4 Financials 4.39%
5 Consumer Discretionary 4.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADBE icon
351
Adobe
ADBE
$103B
$655K 0.01%
1,284
+251
+24% +$132K
ITOS
352
DELISTED
iTeos Therapeutics
ITOS
$654K 0.01%
59,764
+8,000
+15% +$102K
INZY
353
DELISTED
Inozyme Pharma
INZY
$652K 0.01%
155,305
– –
EDIT icon
354
Editas Medicine
EDIT
$445M
$642K 0.01%
82,369
– –
VKTX icon
355
Viking Therapeutics
VKTX
$3.88B
$641K 0.01%
57,905
+16,000
+38% +$229K
AMLX icon
356
Amylyx Pharmaceuticals
AMLX
$2.7B
$641K 0.01%
35,000
-4,000
-10% -$84.6K
AAL icon
357
American Airlines Group
AAL
$10.6B
$641K 0.01%
+50,000
New +$776K
XIFR
358
PUT
XPLR Infrastructure LP
XIFR
$1.08B
$637K 0.01%
+140,000
New +$7.09M
CRL icon
359
Charles River Laboratories
CRL
$12.7B
$629K 0.01%
3,211
– –
TSLA icon
360
Tesla
TSLA
$1.26T
$626K 0.01%
2,500
-1,000
-29% -$257K
ESPR
361
DELISTED
Esperion Therapeutics
ESPR
$619K 0.01%
631,947
+335,000
+113% +$485K
HIW icon
362
Highwoods Properties
HIW
$3.47B
$618K 0.01%
30,000
-70,000
-70% -$1.66M
HLN icon
363
Haleon
HLN
$44.2B
$618K 0.01%
74,185
-180,000
-71% -$1.5M
GPCR icon
364
Structure Therapeutics
GPCR
$3.74B
$616K 0.01%
12,218
+2,025
+20% +$65.3K
INBX
365
DELISTED
Inhibrx, Inc. Common Stock
INBX
$614K 0.01%
33,448
– –
ELAN icon
366
Elanco Animal Health
ELAN
$12.1B
$609K 0.01%
54,176
– –
PLTR icon
367
Palantir
PLTR
$375B
$600K 0.01%
37,500
+17,727
+90% +$282K
EVLVW
368
DELISTED
Evolv Technologies Warrant
EVLVW
$600K 0.01%
693,200
– –
QURE icon
369
uniQure
QURE
$3.15B
$597K 0.01%
88,965
-55,000
-38% -$495K
MRK icon
370
Merck
MRK
$317B
$596K 0.01%
5,790
– –
CRNX icon
371
CALL
Crinetics Pharmaceuticals
CRNX
$8.9B
$588K 0.01%
+60,000
New +$1.24M
TRIP icon
372
TripAdvisor
TRIP
$1.22B
$580K 0.01%
35,000
– –
F icon
373
PUT
Ford
F
$55B
$576K 0.01%
740,900
– –
OVID icon
374
Ovid Therapeutics
OVID
$495M
$576K 0.01%
150,000
+20,000
+15% +$71.9K
BGS icon
375
PUT
B&G Foods
BGS
$278M
$555K 0.01%
215,000
– –
13 14
15
16 17

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
SAG
SageView Advisory Group Newport Beach, California $2.96B AUM 15.81% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
TCOV
Trust Company of Vermont Brattleboro, Vermont $2.4B AUM 18.8% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return

UBS O'Connor's Q3 2023 Portfolio in Review

As of Q3 2023, UBS O'Connor held 710 positions worth $5.62B, up 18% from $4.75B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

UBS O'Connor deployed $536M of net new capital in Q3 2023, opening 128 new positions and adding to 146 existing holdings. Its largest new stake was Denbury Inc.: 1,931,731 shares worth $189M.

By sector, the portfolio is most concentrated in Technology at 35% of assets, up from 16% a quarter earlier, followed by Healthcare and Real Estate.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $19.7M trimmed.

  • UBS O'Connor's largest Q3 2023 buy was Denbury Inc.: 1,931,731 shares worth $189M.
  • UBS O'Connor added most to Activision Blizzard in Q3 2023, an estimated $779M increase.
  • UBS O'Connor's biggest Q3 2023 reduction was Seagen Inc. Common Stock, cutting an estimated $19.7M.
  • UBS O'Connor fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $230M.
  • UBS O'Connor's ten largest holdings make up 66% of its $5.62B portfolio in Q3 2023.
  • UBS O'Connor opened 128 new positions and closed 149 in Q3 2023.
  • UBS O'Connor's portfolio value rose 18% quarter-over-quarter to $5.62B.

Based on UBS O'Connor's 13F filing for Q3 2023, filed 14 Nov 2023.